Financials data is unavailable for this security.
View more
Year on year Torii Pharmaceutical Co Ltd grew revenues 11.74% from 48.90bn to 54.64bn while net income improved 4.46% from 3.94bn to 4.12bn.
| Gross margin | 44.46% |
|---|---|
| Net profit margin | 8.97% |
| Operating margin | 10.93% |
| Return on assets | 3.96% |
|---|---|
| Return on equity | 4.42% |
| Return on investment | 4.39% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Torii Pharmaceutical Co Ltd fell by 10.74bn. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 3.12bn. In addition the company used 3.78bn on investing activities and also paid 3.84bn in financing cash flows.
| Cash flow per share | 202.68 |
|---|---|
| Price/Cash flow per share | 23.58 |
| Book value per share | 4,271.84 |
|---|---|
| Tangible book value per share | 4,259.53 |
More ▼
Balance sheet in JPYView more
| Current ratio | 6.14 |
|---|---|
| Quick ratio | 5.19 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 20.00% and 4.41%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 2.33% |
|---|---|
| Div growth rate (5 year) | 20.11% |
| Payout ratio (TTM) | 69.24% |
| EPS growth(5 years) | 28.71 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 52.63 |
More ▼
